Look­ing to grow block­buster Po­m­a­lyst fran­chise, Cel­gene de­clares a win for mul­ti­ple myelo­ma triplet in piv­otal PhI­II

Re­searchers for Cel­gene say that they hit the pri­ma­ry end­point for OP­TI­MIS­MM, a piv­otal Phase III for treat­ment-re­sis­tant mul­ti­ple myelo­ma that com­bined Po­m­a­lyst with borte­zomib (Vel­cade) and low-dose dex­am­etha­sone com­pared to a com­bi­na­tion of the last two alone.

The com­pa­ny is hold­ing back the num­bers for a sci­en­tif­ic con­fer­ence, but the com­pa­ny said that the study “achieved its pri­ma­ry end­point, show­ing a sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment in pro­gres­sion-free sur­vival for the po­ma­lido­mide arm ver­sus the com­para­tor arm.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.